- Alpha Cognition (CSE:ACOG) announced encouraging interim preclinical data supporting the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI)
- This data highlights the potential benefits of ALPHA-1062 in treating mTBI resulting from repetitive blast trauma, a prevalent injury among military personnel exposed to explosive devices and artillery fire
- Interim results demonstrate that ALPHA-1062 administration significantly reduces TBI-associated neuropathology
- Alpha Cognition stock (CSE:ACOG) last traded at C$7.95
Alpha Cognition (CSE:ACOG) announced encouraging interim preclinical data supporting the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI).
This data highlights the potential benefits of ALPHA-1062 in treating mTBI resulting from repetitive blast trauma, a prevalent injury among military personnel exposed to explosive devices and artillery fire.
The team had previously documented significant functional and neuropathological protection provided by ALPHA-1062 following a single moderate traumatic brain injury. The current study, conducted in collaboration with the Seattle Institute of Biomedical and Clinical Research and supported by the U.S. Department of Defense, focuses on a rodent model subjected to three consecutive days of blast-induced mTBI.
Interim results demonstrate that ALPHA-1062 administration significantly reduces TBI-associated neuropathology. Key findings include a reduction in neuroinflammation markers and neuropathology post-blast trauma. High doses of ALPHA-1062 notably decreased myeloid cell activation across multiple brain regions one month after the blast and reduced midbrain astrogliosis, a process where astrocytes enlarge and multiply in response to brain injury.
“These outcomes indicate a protective effect of ALPHA-1062 and demonstrate a reduction in neuropathology,” Denis Kay, the company’s chief scientific officer said in a news release. “The data provide further support for the continued development of ALPHA-1062 for the treatment of acute mild traumatic brain injury.”
The study is ongoing, with further analysis of neuropathology and neurobehavioral data expected. The final study report is anticipated in Q2 2025.
Alpha Cognition is a clinical-stage biopharmaceutical company developing treatments for underserved neurodegenerative diseases.
Alpha Cognition stock (CSE:ACOG) last traded at C$7.95 and has fallen 51.82 per cent since the year began.
Join the discussion: Find out what everybody’s saying about this stock on the Alpha Cognition Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top photo via Alpha Cognition Inc.)